PMC Articles for PubChem Compound (Select 86292849) - PMC

Result Filters

Links from PubChem Compound

Items: 16

Select item 109371991.

Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors

B. Perez, R. Aljumaily, T.U. Marron, M.R. Shafique, H. Burris, W.T. Iams, S.J. Chmura, J.J. Luke, W. Edenfield, D. Sohal, X. Liao, C. Boesler, A. Machl, J. Seebeck, A. Becker, B. Guenther, A. Rodriguez-Gutierrez, S.J. Antonia

ESMO Open. 2024 Feb; 9(2): 102217. Published online 2024 Feb 5. doi: 10.1016/j.esmoop.2023.102217

PMCID:: PMC10937199

Abstract Article PDF–473K

Select item 108701142.

A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

Paul B. Romesser, Jaume Capdevila, Rocio Garcia-Carbonero, Tony Philip, Carlos Fernandez Martos, Richard Tuli, Almudena Rodriguez-Gutierrez, Mirjam Kuipers, Andreas Becker, Anna Coenen-Stass, Barbara Sarholz, Xiaoli You, Eric D. Miller

Clin Cancer Res. 2024 Feb 16; 30(4): 695–702. Published online 2023 Dec 5. doi: 10.1158/1078-0432.CCR-23-1129

PMCID:: PMC10870114

Abstract Article PDF–263K

Select item 107194683.

Phase I crossover study of DNA‐protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension

Andreas Becker, Axel Krebs‐Brown, Claudia Vetter, Tanja Reuter, Almudena Rodriguez‐Gutierrez, Xiaoli You, Michael Lissy

Clin Transl Sci. 2023 Dec; 16(12): 2628–2639. Published online 2023 Oct 31. doi: 10.1111/cts.13657

PMCID:: PMC10719468

Abstract Article PDF–5.2M

Select item 95887474.

Targeting DNA repair with combined inhibition of NHEJ and MMEJ induces synthetic lethality in TP53-mutant cancers

Jeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, Carter Grochala, Huy Nguyen, Jia Zhou, Kalindi Parmar, Jean-Bernard Lazaro, Joyce Liu, Kelsey McQueen, Geoffrey I. Shapiro, David Kozono, Alan D. D’Andrea

Cancer Res. Author manuscript; available in PMC 2023 Apr 17.

Published in final edited form as: Cancer Res. 2022 Oct 17; 82(20): 3815–3829. doi: 10.1158/0008-5472.CAN-22-1124

PMCID:: PMC9588747

Abstract Article PDF–2.3M

Select item 95275205.

EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma

Jie Ding, Xiaolong Li, Sabbir Khan, Chen Zhang, Feng Gao, Shayak Sen, Amanda R Wasylishen, Yang Zhao, Guillermina Lozano, Dimpy Koul, W K Alfred Yung

Neuro Oncol. 2022 Oct; 24(10): 1712–1725. Published online 2022 Apr 26. doi: 10.1093/neuonc/noac105

PMCID:: PMC9527520

Abstract Article PDF–12M

Select item 93811106.

DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy

Michael I. Carr, Li-Ya Chiu, Yige Guo, Chunxiao Xu, Adam S. Lazorchak, Huakui Yu, Guozhong Qin, Jin Qi, Bo Marelli, Yan Lan, Qing Sun, Frank Czauderna, Frank T. Zenke, Andree Blaukat, Lyubomir T. Vassilev

Mol Cancer Res. 2022 Apr 1; 20(4): 568–582. Published online 2022 Jan 3. doi: 10.1158/1541-7786.MCR-21-0612

PMCID:: PMC9381110

Abstract Article PDF–1.9M

Select item 92628247.

DNA-PK inhibition and radiation promote anti-tumoral immunity through RNA Polymerase III in pancreatic cancer

Weiwei Wang, Matthew T. McMillan, Xinyi Zhao, Zhuwen Wang, Long Jiang, David Karnak, Fatima Lima, Joshua D. Parsels, Leslie A. Parsels, Theodore S. Lawrence, Timothy L Frankel, Meredith A. Morgan, Michael D. Green, Qiang Zhang

Mol Cancer Res. Author manuscript; available in PMC 2023 Jan 6.

Published in final edited form as: Mol Cancer Res. 2022 Jul 6; 20(7): 1137–1150. doi: 10.1158/1541-7786.MCR-21-0725

PMCID:: PMC9262824

Abstract Article PDF–2.3M

Select item 92093958.

Improved and Flexible HDR Editing by Targeting Introns in iPSCs

Juan Fu, Ya-Wen Fu, Juan-Juan Zhao, Zhi-Xue Yang, Si-Ang Li, Guo-Hua Li, Zi-Jun Quan, Feng Zhang, Jian-Ping Zhang, Xiao-Bing Zhang, Chang-Kai Sun

Stem Cell Rev Rep. 2022; 18(5): 1822–1833. Published online 2022 Jan 28. doi: 10.1007/s12015-022-10331-1

PMCID:: PMC9209395

Abstract Article PDF–2.1M

Select item 91902349.

Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases

Surabhi Talele, Wenjuan Zhang, Ju-Hee Oh, Danielle M. Burgenske, Ann C. Mladek, Sonja Dragojevic, Jann N. Sarkaria, William F. Elmquist

J Pharmacol Exp Ther. 2022 Jun; 381(3): 217–228. Published online 2022 Jun. doi: 10.1124/jpet.121.001069

Correction in:: J Pharmacol Exp Ther. 2022 Dec; 383(3): 251.

PMCID:: PMC9190234

Abstract Article PDF–1.4M

Select item 903222810.

Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy

Yoshihisa Matsumoto

Int J Mol Sci. 2022 Apr; 23(8): 4264. Published online 2022 Apr 12. doi: 10.3390/ijms23084264

PMCID:: PMC9032228

Abstract Article PDF–3.6M

Select item 885066111.

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer

Mary Smithson, Regina K. Irwin, Gregory Williams, M. Chandler McLeod, E. Karen Choi, Anutosh Ganguly, Ashley Pepple, Clifford S. Cho, Christopher D. Willey, Judith Leopold, Karin M. Hardiman

Neoplasia. 2022 Mar; 25: 53–61. Published online 2022 Feb 12. doi: 10.1016/j.neo.2022.01.004

PMCID:: PMC8850661

Abstract Article PDF–2.2M

Select item 879183012.

Structural insights into inhibitor regulation of the DNA repair protein DNA-PKcs

Shikang Liang, Sherine E. Thomas, Amanda K. Chaplin, Steven W. Hardwick, Dimitri Y. Chirgadze, Tom L. Blundell

Nature. 2022; 601(7894): 643–648. Published online 2022 Jan 5. doi: 10.1038/s41586-021-04274-9

PMCID:: PMC8791830

Abstract Article PDF–14M

Select item 877062313.

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer

Sushmita B. Gordhandas, Beryl Manning-Geist, Christina Henson, Gopa Iyer, Ginger J. Gardner, Yukio Sonoda, Kathleen N. Moore, Carol Aghajanian, M. Herman Chui, Rachel N. Grisham

Sci Rep. 2022; 12: 974. Published online 2022 Jan 19. doi: 10.1038/s41598-021-04618-5

PMCID:: PMC8770623

Abstract Article PDF–2.6M

Select item 819029614.

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

Eric Haines, Yuki Nishida, Michael I. Carr, Rafael Heinz Montoya, Lauren B. Ostermann, Weiguo Zhang, Frank T. Zenke, Andree Blaukat, Michael Andreeff, Lyubomir T. Vassilev

Sci Rep. 2021; 11: 12148. Published online 2021 Jun 9. doi: 10.1038/s41598-021-90500-3

PMCID:: PMC8190296

Abstract Article PDF–2.6M

Select item 788467915.

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Mark T. J. van Bussel, Ahmad Awada, Maja J. A. de Jonge, Morten Mau-Sørensen, Dorte Nielsen, Patrick Schöffski, Henk M. W. Verheul, Barbara Sarholz, Karin Berghoff, Samer El Bawab, Mirjam Kuipers, Lars Damstrup, Ivan Diaz-Padilla, Jan H. M. Schellens

Br J Cancer. 2021 Feb 16; 124(4): 728–735. Published online 2020 Nov 24. doi: 10.1038/s41416-020-01151-6

PMCID:: PMC7884679

Abstract Article PDF–785K

Select item 574794716.

Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation

Carmen Klein, Ivana Dokic, Andrea Mairani, Stewart Mein, Stephan Brons, Peter Häring, Thomas Haberer, Oliver Jäkel, Astrid Zimmermann, Frank Zenke, Andree Blaukat, Jürgen Debus, Amir Abdollahi

Radiat Oncol. 2017; 12: 208. Published online 2017 Dec 29. doi: 10.1186/s13014-017-0939-0